1. Academic Validation
  2. Structural basis of ligand interaction with atypical chemokine receptor 3

Structural basis of ligand interaction with atypical chemokine receptor 3

  • Nat Commun. 2017 Jan 18;8:14135. doi: 10.1038/ncomms14135.
Martin Gustavsson 1 Liwen Wang 2 Noortje van Gils 1 Bryan S Stephens 1 Penglie Zhang 3 Thomas J Schall 3 Sichun Yang 2 Ruben Abagyan 1 Mark R Chance 2 Irina Kufareva 1 Tracy M Handel 1
Affiliations

Affiliations

  • 1 Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive, MC 0684, La Jolla, California, 92093, USA.
  • 2 Center for Proteomics and Bioinformatics and Department of Nutrition, Case Western Reserve University School of Medicine, 10009 Euclid Avenue, Cleveland, Ohio 44109, USA.
  • 3 ChemoCentryx Inc., 850 W Maude Avenue, Mountain View, California 94043, USA.
Abstract

Chemokines drive cell migration through their interactions with seven-transmembrane (7TM) chemokine receptors on cell surfaces. The atypical Chemokine Receptor 3 (ACKR3) binds chemokines CXCL11 and CXCL12 and signals exclusively through β-arrestin-mediated pathways, without activating canonical G-protein signalling. This receptor is upregulated in numerous cancers making it a potential drug target. Here we collected over 100 distinct structural probes from radiolytic footprinting, disulfide trapping, and mutagenesis to map the structures of ACKR3:CXCL12 and ACKR3:small-molecule complexes, including dynamic regions that proved unresolvable by X-ray crystallography in homologous receptors. The data are integrated with molecular modelling to produce complete and cohesive experimentally driven models that confirm and expand on the existing knowledge of the architecture of receptor:chemokine and receptor:small-molecule complexes. Additionally, we detected and characterized ligand-induced conformational changes in the transmembrane and intracellular regions of ACKR3 that elucidate fundamental structural elements of agonism in this atypical receptor.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-123813
    98.73%, ACKR3 Agonist